When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
OTC company Provectus (OTC:PVCT+3.0%) has announced preliminary data from its Phase 1b/2 study of PV-10 in combination with Merck's KEYTRUDA for the treatment of advanced cutaneous melanoma in patients who did not respond to single- and dual-agent checkpoint blockade (CB) treatment. Data were presented at the European Society for Medical Oncology Virtual Congress.
More news on: Provectus Biopharmaceuticals, Inc., Healthcare stocks news,